Latest News

  • NIDA-Funded Study Evaluating Extended-Release Injectable Naltrexone Plus Bupropion for the Treatment of Methamphetamine Use Disorder Published in New England Journal of Medicine Read More
  • Alkermes to Present at the 39th Annual J.P. Morgan Healthcare Conference Read More
  • Alkermes Announces Updates to Executive Leadership Team Read More
  • FDA Accepts Alkermes' Resubmission of New Drug Application for ALKS 3831 Read More

Investors

Response to Current Events